(Total Views: 472)
Posted On: 10/23/2020 11:00:27 AM
Post# of 148899
Please comment on my understanding as to where things stand.
CYDY down 5.59% in early trading. The reason, FDA's approval of Gilead's treatment for CV19. This is one of the drugs given to Trump pre approval. This drug is far from perfect.
Leronlimab has proven in EIND's to be vastly superior. The phase 3 interim results for s/c are in, but blinded to CYDY. The advisory committee has seen the results, and, has advised CYDY to continue with enrollment to satisfy the trials requirement (63 additional patients).. Also, no other changes are needed. Obviously, the results thus far are good enough for an EUA, or possibly FDA approval. So, it would appear that it's only a matter of time. CYDY shareholder's via Investor's Hangout are highly concerned about FDA big pharma bias.
Interim results can be accessed by CYDY at the cost of a small penalty to the formula used to determine FDA approval. I don't know why the outcome should be penalized for a peek at the interim results. This tie-in makes no sense to me. A number of shareholders via Investor's Hangout are clamoring for CYDY to accept the penalty to see the interim results. The thinking being that the results could then be made public to pressure on the FDA and hasten approval by foreign FDA equivalents. In my opinion this is a viable option at some point, perhaps now.
CYDY down 5.59% in early trading. The reason, FDA's approval of Gilead's treatment for CV19. This is one of the drugs given to Trump pre approval. This drug is far from perfect.
Leronlimab has proven in EIND's to be vastly superior. The phase 3 interim results for s/c are in, but blinded to CYDY. The advisory committee has seen the results, and, has advised CYDY to continue with enrollment to satisfy the trials requirement (63 additional patients).. Also, no other changes are needed. Obviously, the results thus far are good enough for an EUA, or possibly FDA approval. So, it would appear that it's only a matter of time. CYDY shareholder's via Investor's Hangout are highly concerned about FDA big pharma bias.
Interim results can be accessed by CYDY at the cost of a small penalty to the formula used to determine FDA approval. I don't know why the outcome should be penalized for a peek at the interim results. This tie-in makes no sense to me. A number of shareholders via Investor's Hangout are clamoring for CYDY to accept the penalty to see the interim results. The thinking being that the results could then be made public to pressure on the FDA and hasten approval by foreign FDA equivalents. In my opinion this is a viable option at some point, perhaps now.
(2)
(1)Scroll down for more posts ▼
